Investigation of the shortcomings of the CONSORT 2010 statement for the reporting of group sequential randomised controlled trials

Munya Dimairo

Acknowledgements to collaborators:

Stevely A, Todd S, Julious S, Nicholl J, Hind D, and Cooper C



#ICTMC2015



Outline

☐ Rationale for the investigation

☐ Addressing research questions

☐ Results

☐ Conclusion and recommendations

□ Acknowledgements and references

Rationale for the investigation ...

Adaptive designs are underused

Recent research uncovered some concerns among key stakeholders (Dimairo

```
et al, 2015)
```

- Could this be linked to the reporting of the conduct of adaptive trials?
- What is the current state of reporting the most common used adaptive

design?

Addressing the research question ...

- ☐ Methodological systematic review
 - ➤ Parallel group and confirmatory GS RCTs (2001 to 23rd Sept 2014)
 - Free text search of terms associated with GS methods via Ovid MEDLINE
 - >Two independent reviewers examined compliance in reporting
 - ➤ Reporting compliance classification system
 - >Used 'all' accessible trial related publications to assess compliance, such

as protocols and prior publications


Results(1): Characteristics of reviewed trials

- ➤68/284 (24%) were eligible GS RCTs
- The majority were published in 'high impact' journals
 - Median (IQR) IF was 17.5 (6.6 to 30.4), with a max of 54 (2013 to 2014)
- ►76% were in oncology
- ≥91% investigating pharmacological interventions
- ▶68% publishing journals endorsed the CONSORT statement
- ▶46(68%) were stopped early: 28 futility, 10 efficacy, ...

Results(2): Reporting compliance to CONSORT checklist

- Most items were better reported: median(IQR);
 - 'complete' compliance of 81% (53% to 91%), with min of 12%
 - 'at least partially complete' compliance of 93% (78% to 97%), with min of 22%
- HOWEVER, suboptimal reporting of items relating to:
 - ➤ Methods used to generate the randomisation list(s) (47%),
 - ➤ Details of randomisation concealment (74%),
 - ➤ Implementation of randomisation (59%),
 - ➤ Details of additional analysis (43%),
 - ➤ Disclosure of trial registration information (38%),
 - ➤ Disclosure and access to full trial protocols (53%).

Results(3): Reporting compliance of GS specific aspects



Conclusions and Recommendations

- Poor reporting of group sequential specific aspects
- Assurance of scientific rigour through transparent adequate reporting is paramount to the credibility of findings from adaptive trials
- Case studies of adaptive designs are only useful when adequately reported
- Urgent need for a CONSORT extension tailored for adaptive designs in general

Acknowledgements

- NIHR DRF Funding (Grant Number: DRF-2012-05-182)
- Fellowship Supervisors
 - Prof Steven Julious
 - Prof Susan Todd
 - Prof Jon Nicholl
- Fellowship Advisory Panel Members
- Abigail Stevely for the support as part of her internship

References




An Investigation of the Shortcomings of the CONSORT 2010 Statement for the Reporting of Group Sequential Randomised Controlled Trials: A Methodological Systematic Review

Abigail Stevely, Munyaradzi Dimairo

, Susan Todd, Steven A. Julious, Jonathan Nicholl, Daniel Hind, Cindy L. Cooper Published: November 3, 2015

DOI: 10.1371/journal.pone.0141104



Detry M, Lewis R, Broglio K et al (2012) Standards for the Design, Conduct, and Evaluation of Adaptive Randomized Clinical Trials